TIME convened the first-ever TIME100 Health Leadership Forum to bring together individuals driving innovation and creating ...

Jefferies analyst Akash Tewari has assigned their bullish stance on ARVN stock, giving a Buy rating yesterday. Akash Tewari’s rating is ...

The Industry is on the brink of a substantial surge, with the market size expected to reach USD 100 Million in 2023 and ...

Empowering young women with the confidence to excel in their education is key to inspiring the next generation' ...

Immutep (ASX:IMM) has made significant progress over the past year with its lead immunotherapy candidate, eftilagimod alpha ...

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer aft ...

Standigm uses Synthia Retrosynthesis Software from Merck KGaA, Darmstadt, Germany, to accelerate its drug design and synthesis processes driving advancements in pharmaceutical development. Standigm ...

Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat. Find out why ...

During the monitoring period, after the seasonal influenza period had ended, 59 wastewater treatment plants showed increases ...

A new study has unveiled crucial information about the incidence and risk factors of oral human papillomavirus (HPV) infections among men in the United States, Mexico and Brazil. Moffitt Cancer Center ...